Series A - Gemini Therapeutics
Investment Firm
Overview
Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Announced Date
Oct 17, 2017
Funding Type
Series A
Highlights
Location
United States, North America
Social
Investor Lead
Atlas Venture
Atlas Venture is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.
Lightstone Ventures
Lightstone Ventures is a early_stage_venture and late_stage_venture and private_equity and venture firm.
OrbiMed
OrbiMed is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Participant Investors
3
| Investor Name |
|---|
Round Details and Background
Gemini Therapeutics raised $42500000 on 2017-10-17 in Series A
Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Company Funding History
3
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Feb 08, 2021 |  Post-IPO Equity - Gemini Therapeutics | 12 | - | 95.0M |
| Oct 17, 2017 | Series A - Gemini Therapeutics | 3 | - | 42.5M |
| Apr 19, 2016 | Seed Round - Gemini Therapeutics | 3 | - | 2.0M |
Recent Activity
There is no recent news or activity for this profile.